Findings

What do systematic reviews say?

4,315 questions · 23,557 findings · 2,311 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4,183 · 17.8%GRADE not reported 3,930 · 16.7%Very low 5,371 · 22.8%Low 5,787 · 24.6%Moderate 3,320 · 14.1%High 966 · 4.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 183 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Grip strength ‐ Vitamin D · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Effect on breast cancer‐specific quality of life (BCS‐QoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Health‐related quality of life (HRQoL) · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 208 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1250 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in grip strength · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 1.08 [0.37, 3.17]
1 study · 137 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Safety of systemic therapies for the treatment of AIMSS · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 344 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Effect on discontinuation of aromatase inhibitors (AI) · women with early breast cancer

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.16 [0.01, 2.99]
1 study · 147 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Effect on breast cancer‐specific quality of life (BCS‐QoL) · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Health‐related quality of life (HRQoL) · women with early breast cancer

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

Summary of findings table ‐ Systemic therapy vs control

Incidence of AIMSS · women with early breast cancer

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
RR 0.82 [0.63, 1.06]
2 studies · 240 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in pain from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1099 participants
Very low

Summary of findings table ‐ Systemic therapy vs control

Change in stiffness from baseline to end of intervention · health problem or population

1 finding from 1 review

Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 295 participants
Very low

Effects of high‐ vs low‐added sugar consumption

Cardiovascular events · Adults without diabetes or CVD

The review found no eligible studies for this question.

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Effects of high‐ vs low‐added sugar consumption

All‐cause mortality · Adults without diabetes or CVD

The review found no eligible studies for this question.

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Effects of high‐ vs low‐added sugar consumption

Cholesterol mg/dL · Adults without diabetes or CVD

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 763 participants
Low

Effects of high‐ vs low‐added sugar consumption

LDL‐cholesterol · Adults without diabetes or CVD

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 712 participants
Low

Effects of high‐ vs low‐added sugar consumption

HDL‐cholesterol · Adults without diabetes or CVD

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 817 participants
Low

Effects of high‐ vs low‐added sugar consumption

Fasting blood glucose (mg/dL) · Adults without diabetes or CVD

1 finding from 1 review

High versus low‐added sugar consumption for the primary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 720 participants
Low

Metformin vs placebo or no treatment

Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported